control for E. coli ATCC 25922 and P. aeruginosa ATCC 27853, and using flucytosine and amphotericin B as the internal controls for C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 showed that 99.8% of all participant MIC results (1,399 values) were within published NCCLS guidelines (5) . Inoculum colony counts were performed from the broth microdilution panels by subculturing in a quantitative manner onto drugfree plates. The inoculum counts for the bacterial QC testing ranged from 1.0 ϫ 10 5 to 5.3 ϫ 10 5 CFU/ml (average inoculum, 3.1 ϫ 10 5 CFU/ml), and those for the yeast QC tests ranged from 5.5 ϫ 10 2 to 4.5 ϫ 10 3 CFU/ml (average inoculum, 2.1 ϫ 10 3 CFU/ml). Proposed QC ranges were optimized to encompass Ն95% of all results as recommended by the NCCLS M23-A2 guideline (3) . MIC results for each tested antimicrobial agent were tabulated and compared by intra-and interlaboratory analysis and by medium lots. The bacterial QC strains were tested in CA-MHB and MHB, and these values were compared.
The results for E. faecalis ATCC 29212 did not show any shift due to the medium divalent cation differences (CA-MHB versus MHB). The modal value for both medium types was 64 g/ml, with 75.5% of the total omiganan MIC results in CA-MHB and 90.0% of the total results in MHB achieving this value. The proposed omiganan MIC QC ranges for both CA-MHB and MHB were 32 to 128 g/ml and encompassed 100% of all participant results. For S. aureus ATCC 29213, 57.1% of all results using CA-MHB and 58.1% of all results using MHB were at the modal value of 16 g/ml. However, the proposed omiganan MIC QC ranges for CA-MHB (8 to 64 g/ml) versus MHB (4 to 32 g/ml) varied by 1 log 2 dilution step (4 log 2 dilution ranges).
S. pneumoniae ATCC 49619 and E. coli ATCC 25922 had similar medium-specific shifts, with MICs being 1 log 2 dilution lower for the MHB than for CA-MHB. S. pneumoniae ATCC 49619 had a modal value of 64 g/ml (75.7% of total results) in the CA-MHB versus a value of 32 g/ml (92.4% of total results) in the MHB. Thus, the proposed 3 log 2 dilution omiganan MIC QC range saw a twofold shift for CA-MHB (32 to 128 g/ml) versus MHB (16 to 64 g/ml). Both ranges included all of the reported results. E. coli ATCC 25922 had a modal value of 32 g/ml (75.7% of total results) in the CA-MHB compared to a 16 g/ml (80.5% of total results) in the MHB. The proposed omiganan MIC QC ranges also were 1 log 2 dilution higher for CA-MHB when E. coli ATCC 25922 was used (Table 1).
P. aeruginosa ATCC 27853 QC trials exhibited a 2-log 2 -dilution difference in the modal omiganan values and proposed MIC QC ranges for CA-MHB and MHB. The modal value in CA-MHB was 128 g/ml (86.7% of total results) compared to MICs in MHB of 32 g/ml (60.0% of total results). The proposed omiganan MIC QC range for CA-MHB was 64 to 256 g/ml, and that for MHB was 8 to 64 g/ml. The cations in the media did not affect all QC strains in the same manner, so it is important to note the differences that medium selection makes for some QC strains, most notably P. aeruginosa ATCC 27853. Table 1 also shows the distribution of omiganan MICs for the two yeast QC strains. A total of 49.5% of the results for C. parapsilosis ATCC 22019 were at the modal value of 64 g/ml.
The proposed omiganan MIC QC range of 32 to 128 g/ml included 99.0% of all reported results. The modal value for C. krusei ATCC 6258 was 32 g/ml (53.8% of results). The proposed omiganan MIC QC range of 16 to 64 g/ml for C. krusei ATCC 6258 includes all reported results.
This study established QC results from a NCCLS M23-A2 (3) study design for omiganan tested by broth microdilution methods (4) (5) (6) . Three log 2 dilution ranges (mode Ϯ 1 log 2 dilution) were established for nine QC organism-medium ranges. Only on three occasions was it necessary to assign a 4-log 2 -dilution range, where nearly equal numbers of omiganan MICs occurred at two adjacent dilution steps (S. aureus ATCC 29213 in CA-MHB and MHB and P. aeruginosa ATCC 27853 in MHB). As omiganan advances through phase III clinical trials and beyond, the MIC QC ranges established during this study will permit accurate laboratory susceptibility testing as an aid in assessing the value of the compound against contemporary cutaneous bacterial isolates or for detection of emerging resistances as part of local or regional epidemiology programs. The latter applications would be similar to those currently used in in vitro tests of mupirocin, another topical agent, to confirm resistances in clinically refractory strains or to select topical agents for formulary addition (1) .
